Pharmaceuticals Related Topics 
Fierce Healthcare
MAY 23, 2022
American Cancer Society, Teva Pharmaceuticals launch coalition to advocate for equity through digital health. agliadkovskaya. Mon, 05/23/2022 - 16:43
Fierce Healthcare
MAY 13, 2022
Industry Voices—How the pharmaceutical industry can turn the tide on mental health. pminemyer. Fri, 05/13/2022 - 10:15
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
AUGUST 23, 2022
BCBS of Vermont sues Teva Pharmaceuticals over marketing for its MS drug Copaxone. fdiamond. Tue, 08/23/2022 - 15:07
NASHP
JANUARY 1, 2023
The post 2023 State Legislative Action to Lower Pharmaceutical Costs appeared first on NASHP. Updated January 20, 2023 Explore the status of state legislation to address prescription drug costs using the map and chart below.
Healthcare ECONOMIST
JULY 1, 2022
2022) measures the relationship between pharmaceutical innovation and longevity. Both figures are well below per capita GDP in the respective regions, suggesting that, overall, pharmaceutical innovation was highly cost-effective. International Health Care Systems Pharmaceuticals InnovationUsing data from 2006-2018 across 26 high-income countries, Lichtenberg et al.
NASHP
SEPTEMBER 22, 2021
2021 State Legislative Action to Lower Pharmaceutical Costs Updated September 22, 2021. Find the status of state legislation to address prescription drug costs below. Use the category button to search by type of legislation and roll over a state to view its pending drug legislation.
Healthcare ECONOMIST
SEPTEMBER 15, 2021
Is it new surgical techniques, better diagnostics, improved medical devices, or new pharmaceuticals? Based on physicians responses, across all 8 diseases , pharmaceuticals had the largest impact on health. Across all 8 diseases 56% of the relative value came from pharmaceuticals.
Bill of Health
JULY 20, 2022
Section 340B of the Public Health Service Act requires that pharmaceutical manufacturers give discounts on specified outpatient drugs to certain covered entities who typically serve low-income or otherwise underserved patients, including hospitals and clinics.
Healthcare Law Blog
NOVEMBER 21, 2022
Pharmaceutical manufacturers are challenging the breadth of the Federal Anti-Kickback Statute (“AKS”) in federal court, arguing that the government is harming the very vulnerable patients it aims to serve by prohibiting cost-sharing subsidies for life-saving oncology drugs.
Healthcare Law Blog
OCTOBER 13, 2022
22-19 (the “Opinion”), which limits the ability of pharmaceutical manufacturers to offer cost-sharing subsidies to Medicare Part D (“Part D”) beneficiaries via 501(c)(3) charities without running afoul of the Federal Anti-Kickback Statute (the “AKS”).
Holland & Knight
FEBRUARY 14, 2022
Shannon Britton Hartsfield
Bill Of Health
OCTOBER 29, 2021
The Doha Declaration , enacted in 2001, attempts to address global inequities stemming from intellectual property protections by allowing countries to grant compulsory licenses for the production of pharmaceuticals for international exports.
Bill Of Health
OCTOBER 15, 2021
Once that knowledge was transferred to the private sector, these private pharmaceutical companies became the holders of the knowledge, related intellectual property, and regulatory dossiers that are needed to bring the products to market. By Ellen ‘t Hoen.
Bill Of Health
DECEMBER 10, 2021
As publicly traded entities, pharmaceutical companies are under legal obligations to maximize shareholder value , not to act in the interests of public health. By Jennifer S.
Bill Of Health
DECEMBER 17, 2021
By Jennifer S. One of the most frightening aspects of the ongoing COVID-19 pandemic has been the lack of a recognized and trusted source of health and safety information.
Bill Of Health
AUGUST 6, 2021
However, since each disease affects less than one person in every 2,000, the pharmaceutical industry has traditionally been reluctant to invest in research and development connected to such illnesses given the small market.
Bill Of Health
AUGUST 26, 2021
Government Pharmaceutical Development to Address High Prices: Challenges Ahead. Kesselheim aging Ameet Sarpatwari Beatrice Brown FDA Health Law Policy Patient Care Pharmaceuticals PORTAL Round-Up Professional Regulation aducanumab Alzheimer's disease cancer generic drugs
Bill Of Health
JANUARY 6, 2022
By Mason Marks. On Tuesday, Washington State legislators filed SB 5660 , a bill that would legalize the supported adult use of psilocybin by people 21 years of age and older.
Bill Of Health
SEPTEMBER 24, 2021
Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based? Ameet Sarpatwari , Beatrice Brown , Alexander Egilman , Aviva Wang, and? Aaron S. Kesselheim.
Bill Of Health
NOVEMBER 12, 2021
By Jennifer S. Over the past two weeks, the news coming in about the spread of COVID-19 has been eerily familiar.
Bill of Health
NOVEMBER 9, 2022
Bioethics Biotechnology FDA FDA in the 21st Century Conference Matthew Chun Medical Safety Pharmaceuticals access to medicine Book Review drug law drug regulation Patient autonomy pharmaceuticalBy Matthew Chun.
Bill Of Health
AUGUST 31, 2021
By Rachel Rebouché. Before the end of 2021, the U.S. Food and Drug Administration (FDA) will reconsider its restrictions on medication abortion.
Healthcare ECONOMIST
JANUARY 23, 2023
HC Statistics Pharmaceuticals Regulation Biosimilars FDA FDA ApprovalsThe year 2022 was a good, but perhaps not great year for innovation.
Bill of Health
DECEMBER 29, 2022
Bioethics Biotechnology Disability Health Law Policy Petrie-Flom Center Pharmaceuticals Public Health coronavirus coronavirus pandemic COVID-19 COVID19 microdosing nate holdren poplar psilocybin social murderBy Chloe Reichel.
Healthcare ECONOMIST
JUNE 3, 2022
Current Events Pharmaceuticals Generic drugs GenericsThat is part due to the squeeze on generic drug pricing from group purchasing organizations and others. This 60 Minutes report is interesting.
Bill Of Health
OCTOBER 6, 2021
By Govind Persad , Patricia J. Zettler , and Holly Fernandez Lynch. As children are experiencing the highest rates of COVID-19 in many states , can efforts to universally preclude vaccination of those under 12 until the U.S.
Bill Of Health
DECEMBER 22, 2021
This post was originally published on the Verfassungsblog as part of our joint symposium on international pandemic lawmaking. By Paul Ogendi.
Bill Of Health
SEPTEMBER 2, 2021
Bioethics FDA Featured Health Law Policy Jennifer Bard Judicial Opinions Medical Safety Off-Label Use Patient Care Pharmaceuticals Professional Regulation Public Health Autonomy coronavirus coronavirus pandemic COVID-19 COVID19 ivermectin jennifer bard Ohio public health research ethics
Health Care Dive
OCTOBER 4, 2021
Allen Meadows worked with Teva Pharmaceuticals to share his experience with the Digihaler® family of inhalers and accompanying platforms
Healthcare ECONOMIST
JANUARY 18, 2023
That is the takeaway according to a November-December 2022 survey by PhRMA of 25 large pharmaceutical manufacturers. Pharmaceuticals Public PolicyAmong respondents, it was clear the IRA price setting provisions are already impacting, and are expected to have a growing impact on, R&D plans moving forward: • 78% expect to cancel early-state pipeline projects. • 63% said they expect to shift R&D investment focus away from small molecule medicines. •
Bill Of Health
NOVEMBER 17, 2021
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Kesselheim Ameet Sarpatwari Beatrice Brown FDA Health Law Policy Pharmaceuticals PORTAL Round-Up PORTALAmeet Sarpatwari , Beatrice Brown , Alexander Egilman , and? Aaron S. Kesselheim.
Bill of Health
OCTOBER 28, 2022
The selections feature topics ranging from an examination of Park doctrine prosecutions of executives of pharmaceutical and medical device companies, an analysis of patent thickets covering biologic drugs, and a discussion of product hopping strategies among manufacturers of inhalers.
Bill Of Health
OCTOBER 13, 2021
By Ana Santos Rutschman. The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines against emerging pathogens.
Bill Of Health
SEPTEMBER 17, 2021
At the start of the 2020s, as the types of pharmaceutical innovations to launch became much more specialist, the companies behind these launches also evolved. Join the author today for the 2021 CeBIL Symposium. Register here! By Sarah Rickwood. The 2020s are the age of orphan medicines.
Bill of Health
NOVEMBER 30, 2022
As a result, the question of whether states can restrict or ban pharmaceuticals approved by the U.S. The FDA achieves its congressionally charged mission , in part, through its gatekeeping function as the primary regulator of pharmaceuticals in the United States.
Bill of Health
NOVEMBER 28, 2022
In 2021, the total revenue of Italian pharmacies dropped by 4% compared to 2015, despite Italy being the fifth largest country in the EU for pharmaceutical expenditures. By Gianluca Ceci and Sarah Gabriele.
Bill Of Health
JANUARY 4, 2022
Kesselheim Ameet Sarpatwari Beatrice Brown Health Law Policy Pharmaceuticals PORTAL Round-Up Vaccines PORTALAmeet Sarpatwari , Beatrice Brown , Aviva Wang, and? Aaron S. Kesselheim.
Healthcare Dive
JANUARY 19, 2023
Previously, Adam Kautzner led pharmaceutical and retail network contracting and drug sourcing as vice president of supply chain for the PBM and Accredo Pharmacy
Bill Of Health
NOVEMBER 10, 2021
The plan places a $2,000 cap on out-of-pocket spending on pharmaceuticals for seniors enrolled in Medicare Part D, which currently covers 48 million people, or 77% of all Medicare beneficiaries. As it stands, Medicare has no cost-sharing cap on pharmaceuticals. By Cathy Zhang.
Bill of Health
JANUARY 18, 2023
Kesselheim Abortion Ameet Sarpatwari Intellectual Property Pharmaceuticals PORTAL Round-Up Publications antitrust Drug Pricing medication abortion patent thicket PORTALBy Ameet Sarpatwari , A viva Wang , and Aaron S. Kesselheim.
Health Populi
JUNE 8, 2022
Tallying up the years between her working in physician practice management and the pharmaceutical sector, as well as time spent in health advocacy, “I’ve been 25 years in health care,” Stacy calculated.
Healthcare ECONOMIST
JANUARY 3, 2023
Health Insurance Pharmaceuticals Adherence Cost Cost sharing HCRU Medication SLR Systematic Literature ReviewThis is the paraphrased title of a paper by Fusco et al. 2023).
Healthcare ECONOMIST
OCTOBER 3, 2022
HC Statistics Pharmaceuticals Public Policy Rare disease Orphan DrugsThe answer is provided in a recent white paper by Pearson, Schapiro and Pearson (2022). They use IQVIA data through 2020 across 389 drugs treating 1.8 million individuals.
Expert insights. Personalized for you.
266 
Let's personalize your content